Compare · BCAX vs NVO
BCAX vs NVO
Side-by-side comparison of Bicara Therapeutics Inc. (BCAX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCAX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $168.79B, about 147.1x BCAX ($1.15B).
- Over the past year, BCAX is down 5.7% and NVO is down 30.0% - BCAX leads by 24.4 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 2 for BCAX).
- NVO has more recent analyst coverage (25 ratings vs 16 for BCAX).
- Company
- Bicara Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $17.63+1.88%
- $39.23+2.88%
- Market cap
- $1.15B
- $168.79B
- 1M return
- -19.83%
- -5.98%
- 1Y return
- -5.67%
- -30.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 2
- 4
- Recent ratings
- 16
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BCAX
- Amendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.
- Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- President, COO & Interim CEO Cohlhepp Ryan exercised 17,500 shares at a strike of $3.79 and sold $400,716 worth of shares (17,500 units at $22.90) as part of a pre-agreed trading plan (SEC Form 4)
- Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Bicara Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BMO Capital Markets initiated coverage on Bicara Therapeutics with a new price target
- SEC Form 4 filed by Chief Financial Officer Larson Jennifer
- SEC Form 3 filed by new insider Larson Jennifer
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank